Abstract: A method for diagnosing a disease, such as breast cancer, in a biological sample using spectroscopic data is described. The method involves computer-implemented method that runs an algorithm. The algorithm converts spectroscopic vibrational from the sample into a profile, and scores the profile using a pair of reference profiles. Based on the score and a threshold, it can be determined whether the subject from which the sample was obtained has a disease, and, if so, to what extent. The method also allows detection of early and pre-disease states in subjects based on the detection of signal of low concentration analytes that are indicative of early or incipient disease state. The method is non-invasive, non-subjective, and highly specific and sensitive. The method affords the application of a single standard of diagnostic accuracy, independent of the local availability of expert pathologists.

Abstract: Described are epigenetic biomarkers of breast cancer and their use in breast cancer screening and diagnosing, or to provide disease prognosis in a subject. The epigenetic biomarkers include methylatable regions (MRs), which may be at least one segment from nucleic acid sequences represented in Table 1. Described are also methods of detecting the methylation level of MRs in the subject, the methylation score (mSCORE) of the subject, and using these values to evaluate a breast cancer risk in a subject, or diagnose a subject with breast cancer. Also described are methods of determining a risk of recurrence and disease prognosis in a subject undergoing or having undergone a treatment for breast cancer.

Abstract: The present disclosure concerns particular biomarkers for screening, diagnosing and/or prognosticating colorectal cancer, in particular in an accurate manner. The methods and compositions concern analysis of methylation patterns of one or more of 176 methylatable genomic DNA regions identified as described herein. In particular embodiments there are methods of detecting methylatable regions in genomic sequences.

Abstract: Described are epigenetic biomarkers of breast cancer and their use in breast cancer screening and diagnosing, or to provide disease prognosis in a subject. The epigenetic biomarkers include methylatable regions (MRs), which may be at least one segment from nucleic acid sequences represented in Table 1. Described are also methods of detecting the methylation level of MRs in the subject, the methylation score (mSCORE) of the subject, and using these values to evaluate a breast cancer risk in a subject, or diagnose a subject with breast cancer. Also described are methods of determining a risk of recurrence and disease prognosis in a subject undergoing or having undergone a treatment for breast cancer.

Abstract: The present disclosure concerns particular biomarkers for screening, diagnosing and/or prognosticating colorectal cancer, in particular in an accurate manner. The methods and compositions concern analysis of methylation patterns of one or more of 176 methylatable genomic DNA regions identified as described herein. In particular embodiments there are methods of detecting methylatable regions in genomic sequences.

Abstract: Different combinations of methylation status based biomarkers can be used to test for prostate cancer with high sensitivity and high specificity.

Abstract: The present invention concerns particular biomarkers for diagnosing and/or prognosticating colorectal cancer, in particular in a non-invasive manner. The methods and compositions concern analysis of methylation patterns of one or more genes from a set of 29 genes identified as described herein. In certain embodiments, the gene set includes at least P15.INK4b, SST, GAS7, CNRIP1, and PIK3CG.

Abstract: Different combinations of methylation status based biomarkers can be used to test for breast cancer with high sensitivity and high specificity.

Abstract: Different combinations of methylation status based biomarkers can be used to test for ovarian cancer with high sensitivity and high specificity.

Abstract: The present invention concerns particular biomarkers for diagnosing and/or prognosticating colorectal cancer, in particular in a non-invasive manner. The methods and compositions concern analysis of methylation patterns of one or more genes from a set of 29 genes identified as described herein. In certain embodiments, the gene set includes at least P15.INK4b, SST, GAS7, CNRIP1, and PIK3CG.

Abstract: Different combinations of methylation status based biomarkers can be used to test for breast cancer with high sensitivity and high specificity.

Abstract: Different combinations of methylation status based biomarkers can be used to test for prostate cancer with high sensitivity and high specificity.

Abstract: Different combinations of methylation status based biomarkers can be used to test for prostate cancer with high sensitivity and high specificity.

Abstract: Different combinations of methylation status based biomarkers can be used to test for breast cancer with high sensitivity and high specificity.

Abstract: The present invention concerns particular biomarkers for diagnosing and/or prognosticating colorectal cancer, in particular in a non-invasive manner. The methods and compositions concern analysis of methylation patterns of one or more genes from a set of 29 genes identified as described herein. In certain embodiments, the gene set includes at least P15.INK4b, SST, GAS7, CNRIP1, and PIK3CG.

Abstract: Different combinations of methylation status based biomarkers can be used to test for ovarian cancer with high sensitivity and high specificity.